One common complaint and issue with our healthcare system is
the prevalence of unnecessary testing on patients for what turns out to be both
relatively harmless and serious diseases. All of this extra testing that is
currently done costs patients and insurance companies untold amounts of money
every year. One example of this is patients who visit the doctor complaining of
chest pain being recommended for further testing. A common current test for
patients who are suspected to have obstructive coronary artery disease (CAD) is
called stress myocardial perfusion imaging or MPI. In 2010 alone, more than 10
million MPI’s were performed in the United States. Following an MPI, patients
whose results show probable signs of CAD are subjected to further invasive
testing, which can be dangerous to the patient’s health and expensive, but also
completely necessary if the patient is thought to have such a serious disease.
However, when that sort of invasive testing is done on patients who actually
exhibit little to no signs of CAD upon anatomical examination the testing is
just dangerous to the patient’s health and expensive, with little to no
benefits. A reason this occurs is because MPI can be unreliable in accurately
predicting whether a patient truly needs further invasive testing or not. More
food for thought is that if the MPI test is generating false positive results,
chances are it is also generating false negative results, which means people are
not getting the further testing they need to help diagnose potential heart
issues.
Source: doctorstock.photoshelter.com
Fortunately for us, Big Data has been set upon the this
issue and researchers at a company called CardioDx, Inc. used big data to
research a new way to better predict those who need additional invasive testing
for CAD. The company used the open-source R statistics language to analyze 10
gigabytes of human genome data in order to find genes linked with CAD. After
completing research, they were able to identify 23 genes which were able to
predict the presence of CAD in patients. From this, the team of researchers was
able to create a simple blood test to find those patients who needed more
invasive CAD testing, which they termed the Corus CAD®. The creation of this
test was announced in January of 2011, but clinical testing of the test was
only recently completed, with the results of these clinical studies released
about a month ago.
The results of the clinical study were clear: the new blood
test was more accurate than the current CPI in predicting the occurrence of
coronary artery disease. With a high negative predictive value and high
sensitivity, the test has the potential to be much more efficient and accurate
than the current CPI test. By having a negative predictive value, this means the Corus test will accurately give an accurate negative result to the patient. By using this test, patients and insurance companies
will be saved from millions of unnecessary dollars being spent on perfectly
healthy patients forced to undergo invasive testing. With nearly
10,000 patients coming into American medical centers every day complaining of
chest pain, it is more important than ever to be able to quickly distinguish
those who have serious heart problems from those who are healthy, or have some
other cause of their pain. This is just another example of how Big Data can
transform our lives for the better, with all of this progress coming from a
company using the same open-source software that all of us have access to if we
wish to use it. It makes you think of the possibilities a single dedicated
individual with a good set of data could create to change the world.
Sources:
It was nice informative blog post on coronary artery disease. I found this information very helpful. Thanks for sharing
ReplyDelete